- Candel reports prostate cancer drug's long-term data ahead of FDA filingCandel Therapeutics produced long-term follow-up data that may bolster the case for its prostate cancer drug that's heading to the FDA for marketing approval later this year. The company followed…Endpoints · 2mo ago↗ source
- Post-Hoc Live: Makary's out at FDA and what comes nextMarty Makary resigned as FDA commissioner on Tuesday after a turbulent tenure at the head of the agency. Makary was scheduled to sit down with senior reporter Max Bayer this week at ...Endpoints · 2mo ago↗ source
- <![CDATA[Poll Findings Highlight the Most Anticipated GU Cancer Abstracts at ASCO 2026]]><![CDATA[GU experts identified key abstracts of interest from the upcoming ASCO Annual Meeting via OncLive’s social media.]]>onclive